Population pharmacokinetics of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (Triapine®) in cancer patients.
about
Structure-antiproliferative activity studies on l-proline- and homoproline-4-N-pyrrolidine-3-thiosemicarbazone hybrids and their nickel(ii), palladium(ii) and copper(ii) complexes.Copper(ii) thiosemicarbazone complexes induce marked ROS accumulation and promote nrf2-mediated antioxidant response in highly resistant breast cancer cells.A phase I study of prolonged infusion of triapine in combination with fixed dose rate gemcitabine in patients with advanced solid tumors.Simultaneous determination of the novel thiosemicarbazone anti-cancer agent, Bp4eT, and its main phase I metabolites in plasma: application to a pilot pharmacokinetic study in rats.Strong effect of copper(II) coordination on antiproliferative activity of thiosemicarbazone-piperazine and thiosemicarbazone-morpholine hybrids.Mitochondria: redox metabolism and dysfunction.Targeting the Large Subunit of Human Ribonucleotide Reductase for Cancer Chemotherapy.Redox activation of Fe(III)-thiosemicarbazones and Fe(III)-bleomycin by thioredoxin reductase: specificity of enzymatic redox centers and analysis of reactive species formation by ESR spin trappingNovel 1-acyl-4-substituted semicarbazide derivatives of primaquine - synthesis, cytostatic, antiviral and antioxidative studies.Complex-Formation Ability of Salicylaldehyde Thiosemicarbazone towards ZnII, CuII, FeII, FeIIIand GaIIIIons
P2860
Q31119195-726E5617-C9FF-44E9-B040-E361FA9D4A01Q31172464-6827F96A-66DF-4F22-863D-BCE29256336EQ33402598-FC61D67B-41C2-4563-BE4B-FF1C5DA7A007Q35047321-39A20DAA-2D9F-4EF9-BD24-D572B26AACB0Q35610388-6E45AB30-12BA-44E9-A68D-4BFB29F4DABCQ35944831-30EF8A5C-FF41-4931-BAE9-79A7ECA4D370Q36353167-A46A352F-2EC4-4E8C-AF13-C09642C66BBEQ36844094-51082FEF-4EC0-4DBB-83D1-17E854D0CF42Q39387605-86059793-F89D-4370-8772-8782B1ED27BEQ58572204-C6F6EEE2-EB60-439C-B17E-3ED76628B2C8
P2860
Population pharmacokinetics of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (Triapine®) in cancer patients.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Population pharmacokinetics of ...... Triapine®) in cancer patients.
@ast
Population pharmacokinetics of ...... Triapine®) in cancer patients.
@en
Population pharmacokinetics of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone
@nl
type
label
Population pharmacokinetics of ...... Triapine®) in cancer patients.
@ast
Population pharmacokinetics of ...... Triapine®) in cancer patients.
@en
Population pharmacokinetics of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone
@nl
prefLabel
Population pharmacokinetics of ...... Triapine®) in cancer patients.
@ast
Population pharmacokinetics of ...... Triapine®) in cancer patients.
@en
Population pharmacokinetics of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone
@nl
P2093
P2860
P1476
Population pharmacokinetics of ...... Triapine®) in cancer patients.
@en
P2093
Anne Traynor
Dona Alberti
Jill Kolesar
Kyle Holen
Marcia Pomplun
Richard C Brundage
P2860
P2888
P304
P356
10.1007/S00280-010-1331-Z
P577
2010-05-04T00:00:00Z
P5875
P6179
1027746337